Hims & Hers Investors: Urgent Action Required Amidst Securities Fraud Claims

Hims & Hers Health, Inc. (NYSE: HIMS) is facing a securities fraud class action. Investors who purchased Hims & Hers stock between April 29, 2025, and June 23, 2025, may move to be appointed lead plaintiff by August 25, 2025. The complaint alleges that Hims & Hers made false and misleading statements about its partnership with Novo Nordisk and failed to disclose material facts, resulting in a $22.24 per share, or 34.63%, decline in stock value. Investors can consult with a lawyer by visiting a specific website or contacting Edelson Lechtzin LLP at 844-696-7492 ext. 1.